Research Papers:

Inhibition of primary breast tumor growth and metastasis using a neuropilin-1 transmembrane domain interfering peptide

Alexia Arpel _, Coralie Gamper, Caroline Spenlé, Aurore Fernandez, Laurent Jacob, Nadège Baumlin, Patrice Laquerriere, Gertraud Orend, Gérard Crémel and Dominique Bagnard

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:54723-54732. https://doi.org/10.18632/oncotarget.10101

Metrics: PDF 1825 views  |   HTML 3014 views  |   ?  


Alexia Arpel1,2, Coralie Gamper1, Caroline Spenlé1, Aurore Fernandez1, Laurent Jacob1, Nadège Baumlin1, Patrice Laquerriere2, Gertraud Orend1, Gérard Crémel1, Dominique Bagnard1

1INSERM U 1109, MN3T Laboratory, Labex Medalis, Strasbourg University, Strasbourg, France

2CNRS UMR 7178, Institut Pluridisciplinaire Hubert Curien, Strasbourg University, Strasbourg, France

Correspondence to:

Dominique Bagnard, email: [email protected]

Keywords: neuropilin-1, breast cancer, metastasis, treatment, peptide

Received: September 28, 2015    Accepted: May 28, 2016    Published: June 16, 2016


The transmembrane domains (TMD) in membrane receptors play a key role in cell signaling. As previously shown by us a peptide targeting the TMD of neuropilin-1 (MTP-NRP1), blocks cell proliferation, cell migration and angiogenesis in vitro, and decreases glioblastoma growth in vivo. We now explored the clinical potential of MTP-NRP1 on breast cancer models and demonstrate that MTP-NRP1 blocks proliferation of several breast cancer lines including the MDA-MB-231, a triple negative human breast cancer cell line. In models with long term in vivo administration of the peptide, MTP-NRP1 not only reduced tumor volume but also decreased number and size of breast cancer metastases. Strikingly, treating mice before tumors developed protected from metastasis establishment/formation. Overall, our results report that targeting the TMD of NRP1 in breast cancer is a potent new strategy to fight against breast cancer and related metastasis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10101